Report of BACR workshop on monoclonal antibodies in breast and ovarian cancer, Brasenose College, Oxford March 17-19th 1991. by Leonard, R. C. et al.
Br. J. Cancer (1991), 64, 796-797
1991
MEETING REPORT
Report of BACR Workshop on Monoclonal Antibodies in Breast and
Ovarian Cancer, Brasenose College, Oxford March 17-19th 1991
R.C.F. Leonard, J. Fisken & J.E. Roulston
It is an appropriate time to bring together the various groups
working in the UK on markers of breast and ovarian cancer.
Physicians are interested in the problems of how to use
markers for screening, management of advanced disease and
increasing imaging and therapy targeting. These main areas
of interest formed the basis of the sessions allocated for
paper presentation and discussion.
Screening (Chairman Dr. J.E. Roulston)
Scott (Derby) presented the rationale for screening ofovarian
cancer. Ovarian cancer fulfils the World Health Organisation
definitions for a tumour which should be considered for
screening. It has an incidence ofabout 4,000 cases per annum
in England and Wales (and including Scotland about 4,500
cases). It is a major health problem being the commonest
cause ofdeath from gynaecological cancer and the increase in
incidence is faster than that for breast cancer. Mortality from
this disease has increased substantially over the last 8 years.
We need a better understanding of the natural history of this
neoplasm and it is reasonable to expect that early stage
disease should be detectable more frequently than currently
in the case; 70% of women present with widespread, and
probably incurable disease. Whether ovarian cancer fulfils the
other criteria required for screening i.e. with simple tech-
nology which is acceptable to patients and resulting in better
long term survival remains to be seen. However, it is impor-
tant to emphasise that when two first degree relatives of
someone have the disease there is a 30% risk of ovarian
cancer in the lifetime of that individual. This is almost cer-
tainly a good case for annual screening about the age of 25.
Infertility therapy resulting in ovarian hyperstimulation may
be a further additional risk but this needs to be tested over
time. There is a need for large randomised population studies
and the cost is probably justifiable given the current techno-
logy. This will almost certainly be based on pelvic examina-
tion, ultrasound scanning and possibly blood marker CA125
(see later).
Austoker (London) gave an update of the breast screening
programme. The design assumes that only 25-35% of screen
detected breast cancer patients would benefit from early
detection, the rest simply suffering from the effect of lead
time bias. Early detection therefore, does not necessarily
imply benefit. Currently there are 25,140 cases per annum of
breast cancer and 15,300 deaths. By targeting the groups
aged 55-64 with a 3 yearly single view mammogram it has
been estimated that there will be 6.6 cancers detected (per
1,000 women screened) with a benign to malignant ratio of
1.3-1. This assumes a 67% attendance, a 75% attendance at
recall and a biopsy rate of 1.1%. Thus of 1.5 million women
in that age category invited approximately 1 million attend,
76,000 are recalled resulting in 16,000 biopsies and 7,000
cancers. Out of the approximately 15,300 deaths per annum
it is possible that the screening programme may end up
saving 1,250 lives. So far the screening rates are as predicted.
Jacobs (Cambridge) described the London Hospital Study
screening for ovarian cancer with markers and ultrasound.
The average survival from ovarian cancer at present is about
30% at 5 years. A family history screen produces only
between 1-5% of all ovarian cancers. Screening according to
age, rather than family history, would focus on women over
45 years (half the population) which produces 85% of all
ovarian cancer. Over 22,000 women have been screened and
the current best estimate is that we need to identify high risk
patients from genetic studies. Further work needs to be done
with ultrasonography improving the technique, possibly
Doppler blood flow colour imaging studies and new serum
markers in addition to CA125 need to evaluated. Evidence
that intervention would reduce mortality would require ran-
domised studies.
Management (Chairman Dr J.E. Taylor-Papadimitriou)
Dixon from the Nottingham Breast Group presented clinical
studies on serum markers of disease activity in the manage-
ment of advanced breast cancer. He emphasised the need for
looking at several markers rather than simply concentrating
on one best marker (CA153). A scoring system has been
developed showing the benefit of ESR and CEA in addition
to CA153 for monitoring response. He emphasised the inade-
quacy of UICC/WHO response criteria especially the stable
disease 'dustbin' category, and in a randomised trial the
Nottingham group have shown that patients with basically
chemosensitive disease (according to the marker response)
may derive a substantial survival benefit from continuation
oftherapy as opposed to stopping therapy at the time of best
marker response. These results would need to be tested on a
different patient group using the same markers but the results
are of interest as they contradict the conventional wisdom
about the optimum duration of therapy for responsive
cancers.
Fisken (Edinburgh) gave a resume of a 5 year programme
for examining ovarian cancer markers at various stages of
disease with the aim of finding prognostic markers and alter-
natives to CA125 in the management of advanced disease. In
an exhaustive analysis, few other candidate anti mucins seem
to stand the test ofclinical value other than HMFG2 which is
sometimes elevated where CA125 is unhelpful. Both markers
contribute in a multi variate analysis of prognosis and be-
come important in longitudinal analysis where other power-
ful prognostic presentation indicators such as performance
status become non significant. The data also confirm the
importance of using markers before going to second look
laparotomy because of the high association between marker
positivity and remaining disease. The value of oncoproteins
remains uncertainly although the first attempt to use such a
marker (with the C-neu product) has proved a disappoint-
ment.
Rustin (London) challenged the wisdom ofmanaging ovar-
ian cancer by conventional scanning techniques. He made a
case for CA125 measurement to be more firmly considered in
patient management and has devised a scoring system based
on CA125 for predicting progression. This should help in
deciding whether to continue to stop chemotherapy, but this
requires further prospective testing. Criteria for response ac-
cording to CA125 levels were also proposed.
Price (Nottingham) described the development of clinically
useful antimucin antibodies raised respectively against urin-
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ary mucins and the mucins from breast cancer cells. The
normal orientation of the polymorphic epithelial mucins
always is exterior on cell membrane and mucin expression in
cell cytoplasm is always abnormal. Approximately 55% of a
small group of breast cancer patients with advanced disease
had elevated levels of mucin by the NCRC 48 assay which
has now been developed for commercial testing. The back-
ground to this is that breast cancers secrete mucins which are
detectable with monoclonal antibodies most frequently in
advanced disease and mucins are not elevated in benign
disease. They may well be used for monitoring therapy in
advanced disease and are almost certainly better than CEA.
Epitope mapping of mucin molecular core has shown a
repeat 20 amino acid sequence of which only two or three
may designate specificity for different monoclonals. Thus
NCRC 48 maybe of interest for patient management now
that assay design has been improved.
Milford-Ward (Nottingham) reviewed the problems of
quality control and standardisation in the development of
tumour markers and emphasised the need for an interna-
tional reference standard for CA125 given the variability
between kits which are all designed to measure the same
antigen. This is basically a problem of the standards which
are included in the kits; the problem will not be solved until
international reference standards have been agreed.
Imaging andmolecular investigation (Chairman Dr R.
Leonard)
Sikora (London) gave an overall view of radio immunoscinti-
graphy in cancer management and pointed out the deficien-
cies as well as the benefits of targeting tumour cell proteins
for diagnosis and management.
Steel (Edinburgh) reviewed chromosomal and genetic
changes in EOC and breast cancer. DNA ploidy is a useful
guide to prognosis in both tumours, but particularly in
borderline EOC. Multiple specific chromosome aberrations
have been reported in both diseases and there are almost too
many to be of individual clinical value. Oncogene over ex-
pression characterises both breast and ovarian cancer, partic-
ularly erb B2, ras and myc oncogenes. Work in the tumour
suppressor gene area has also produced some interesting
specific information on deletions and there are parallels
between breast and ovarian cancer but also probably some
very important differences.
Barnes (London) gave some practical guidelines for the
assaying of primary tumour tissues with antibodies, partic-
ulary for fixed paraffin-embedded sections. There are prob-
lems with prognostic factor studies and prognostic factor
evaluation has to be based on biological hypothesis. A pilot
study which looks promising requires to be confirmed by a
definitive study. This demands careful calculation of the sam-
ple size and allowance made for the likely bias in the patient
population selected. Careful validation of the methodology
need to be made and optimal cutoff values defined before the
study is performed. Ultimately the value of such tissue mar-
kers will depend upon their reproducibility.
Britten (London) gave a very positive overview of current
imaging techniques with monoclonals for ovarian cancer. He
emphasised the value of small amounts ofantibody for imag-
ing (around +-1 mg), and the great advantages of being able
to use technetium (Tc9) scanning which allows a current
widely available equipment to be utilised as opposed to the
earlier iodine 123 or indium 111 scans. Imaging over time is
important. A 10 min image is a template followed by images at
6 h and 24 h to provide subtraction scan pictures. Also kinetic
analysis can be performed on the digital information from the
scan which will give greater confidence in the differences from
baseline. The antibodies which are successful for targeting
ovarian cancer include SM3, HMFG2 HMFG,. The accuracy
for detecting pelvic undiagnosed masses is around 97% and
relative uptake for the antibody in malignant vs benign tis-
sues is of the order of 30:1 to 170:1 depending on the
antibody. It is important to get a good signal allowing the
statistical processing can deal with the background noise.
Therapy (Chaiman Professor P. Porter)
Epenetos (London) gave a resume of the targeting studies
with immunotherapy in ovarian cancer. He emphasised the
possibilities of molecular design in improving the functional
characteristics of antibody and was optimistic about the
benefit of targeted therapy in a limited number of clinical
situations, particularly where there is small amount of
remaining disease.
Verhoeyen (Bedford) discussed the modification of murine
monoclonals into humanised forms by genetic engineering.
One such antibody (HMFG1) which is relevant for targeting
ovarian cancer is now being manufactured in therapeutic
quantities.
Sharma (London) described the use of the ADEPT system
of primary antibody linked to pro-drug followed by secon-
dary antibody with enzyme link to activated the pro-drug at
the target site. Work has commenced in the clinic having
refined the system in laboratory animals. One problem has
been to deal with the human antibody mouse antibody
(HAMA) and this has been achieved by enhancing in the
clearance of the HAMA by a secondary exposure to an non
specific mouse antibody. There is no convincing evidence yet
that the ADEPT system has produced improved targeting in
the clinic although the laboratory data look quite promising.
Dr Leonard concluded the conference by emphasising the
positive clinical work that is now emerging particularly in the
area of serum monitoring and radio diagnosis.
The majority of these papers are due to be published in
full in 'Disease Markers'.